ASCO 2022 VL

Immunotherapy and PARP Inhibitors in Biochemical Recurrent Prostate Cancer - Alexandra Sokolova

Details
Alexandra Sokolova joins Alicia Morgans to discuss her work on biochemical recurrent prostate cancer. Dr. Sokolova and her team at OHSU hypothesize that a combination of durvalumab and olaparib will result in a deeper remission, delay the need for ADT, and improve the quality of life for patients who have a shorter PSA doubling time and a higher risk of developing metastasis. Biographies: Alexandr...

How Do the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi

Details
Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well as t...

BRCAAway - a Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC with DNA Repair Defects - Maha Hussain

Details
Maha Hussain is discussing the BRCAAway with Alicia Morgans, based upon Dr Hussain's presentation at ASCO 2022. The BRCAAway Trial is a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with mCRPC with DNA repair defects either in the tumor or germline. The PARP-inhibitor olaparib is approved for mCRPC patients with deleterious germline or somatic homologous...

Overall Survival Outcomes in ENZAMET (ANZUP 1304), Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer - Ian Davis

Details
Ian Davis joins Alicia Morgans in discussing the overall survival (OS) outcomes in ENZAMET (ANZUP 1304), an international, cooperative group randomized phase three cooperative group, open label study, looking at the addition of enzalutamide, for patients with metastatic hormone-sensitive prostate cancer, commencing therapy. At this year's ASCO meeting, Ian Davis presented the updated OS findings f...

The Association of PSA Response and Overall Survival in Patients with mHSPC in the Phase 3 ARASENS Trial - Fred Saad

Details
Fred Saad joins Alicia Morgans in discussing the association between PSA response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial. In the ARASENS trial, the combination of darolutamide plus ADT and docetaxel significantly prolonged the time to PSA progression, and more patients receiving darolutamide vs placebo achieved...

Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg

Details
Cora Sternberg joins Alicia Morgans in discussing subgroup analyses of the phase 3 JAVELIN Bladder 100 trial which demonstrated that first-line avelumab maintenance + best supportive care (BSC) significantly prolonged overall survival compared to BSC alone in patients with advanced urothelial carcinoma that had not progressed during initial induction treatment with platinum-based chemotherapy. Drs...

No Longer ADT Alone in Metastatic Hormone-Sensitive Prostate Cancer, The ARASENS Trial - Cora Sternberg

Details
Cora Sternberg joins Alicia Morgans in a discussion on the treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) highlighting the ARASENS trial. The treatment landscape for mHSPC has become increasingly complex during the last several years. The ARASENS study along with PEACE-1 demonstrated that in patients eligible for treatment with chemotherapy, the addition of abiraterone...

Theranostics in Prostate Cancer Management - The theraP Trial - Michael Hofman

Details
In this conversation, Matthew Cooperberg and Michael Hofman discuss areas of development in the diagnostic and theranostic spaces in prostate cancer management. Dr Hofman highlights the Federal Drug Administration (FDA) approval of PSMA 617, discusses its global accessibility, and the focus on patient selection for this treatment. The theraP trial was a phase III randomized study of 177Lu-PSMA-617...
email news signup